ESMO 2019: Final FLAURA results reinforce front-line approval of AstraZeneca’s Tagrisso

Final results from the Phase III FLAURA trial investigating AstraZeneca’s Tagrissofinal reinforce the therapy as the SOC for first-line treatment of patients with EGFRm advanced NSCLC, according to the study’s author.